Biosig Technologies (NASDAQ:STEX) Director Morgan Lee Lekstrom Acquires 41,000 Shares

Posted by ABMN Staff on Jan 27th, 2026

Biosig Technologies, Inc. (NASDAQ:STEX – Get Free Report) Director Morgan Lee Lekstrom bought 41,000 shares of Biosig Technologies stock in a transaction that occurred on Friday, January 23rd. The stock was purchased at an average price of $3.13 per share, with a total value of $128,330.00. Following the purchase, the director directly owned 48,000 shares in the company, valued at $150,240. The trade was a 585.71% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Biosig Technologies Trading Up 4.6%

Biosig Technologies stock opened at $3.40 on Tuesday. Biosig Technologies, Inc. has a fifty-two week low of $0.40 and a fifty-two week high of $14.11.

Analyst Ratings Changes

Separately, Weiss Ratings initiated coverage on shares of Biosig Technologies in a report on Friday. They issued a “sell (d-)” rating on the stock. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Biosig Technologies presently has a consensus rating of “Sell”.

Check Out Our Latest Stock Report on STEX

Biosig Technologies Company Profile

(Get Free Report)

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.